Published in
Wiley, Diabetes, Obesity and Metabolism, 3(25), p. 748-757, 2022
DOI: 10.1111/dom.14921
Links
Tools
Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
Journal article published in 2022 by
Kristoffer Nilsson 
,
Emelie Andersson,
Katarina Steen Carlsson ,
Sofie Persson ,
Kristina Karlsdotter,
Josefin Skogsberg,
Staffan Gustavsson,
Johan Jendle ,
Katarina Steen Carlsson
,
Emelie Andersson,
Katarina Steen Carlsson ,
Sofie Persson ,
Kristina Karlsdotter,
Josefin Skogsberg,
Staffan Gustavsson,
Johan Jendle ,
Katarina Steen Carlsson
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 